

**UNAUDITED FINANCIAL RESULTS (PROVISIONAL)  
FOR THE QUARTER ENDED 31<sup>st</sup> DECEMBER, 2012**

(Rs. In Millions)

S. No.	PARTICULARS	Quarter Ended on			Nine Months Ended on		Year Ended on
		31/12/2012 Unaudited	30/09/2012 Unaudited	31/12/2011 Unaudited	31/12/2012 Unaudited	31/12/2011 Unaudited	31/03/2012 Audited
	<b>Part - I</b>						
1	<b>Net Sales/ Income from operations</b>						
	Gross Sales	1119.09	1106.63	941.33	3349.47	2,891.29	4,023.91
	Less: Excise Duty	2.85	2.52	1.29	8.78	4.94	7.38
	(a) Net Sales	1116.24	1104.11	940.04	3340.69	2,886.35	4,016.53
	(b) Other Operating Income	10.12	4.02	18.24	19.52	23.12	35.34
	<b>Total Income from Operation ( Net )</b>	<b>1,126.36</b>	<b>1,108.13</b>	<b>958.28</b>	<b>3,360.21</b>	<b>2,909.47</b>	<b>4,051.87</b>
2	<b>Expenses</b>						
	(a) Consumption of raw materials	635.35	652.18	528.58	1939.90	1,674.74	2,350.71
	(b) (Increase)/ Decrease in stock in trade	0.55	-31.90	-2.94	-61.10	-90.54	-90.33
	(c) Employee benefits expense	58.35	58.06	55.93	173.51	166.18	205.78
	(d) Depreciation & amortisation expense	80.09	79.77	61.33	237.55	183.36	240.67
	(e) Other expenses	133.09	141.90	139.18	423.79	392.55	524.69
	<b>Total expense</b>	<b>907.43</b>	<b>900.01</b>	<b>782.08</b>	<b>2,713.65</b>	<b>2,326.29</b>	<b>3,231.52</b>
3	<b>Profit from operations before other income, finance costs and exceptional items ( 1-2)</b>	<b>218.93</b>	<b>208.12</b>	<b>176.20</b>	<b>646.56</b>	<b>583.18</b>	<b>820.35</b>
4	Other income	3.45	2.69	1.02	7.40	1.79	3.80
5	<b>Profit before finance costs and exceptional items ( 3+4)</b>	<b>222.38</b>	<b>210.81</b>	<b>177.22</b>	<b>653.96</b>	<b>584.97</b>	<b>824.15</b>
6	Finance Costs	52.94	53.72	66.81	182.81	186.38	272.64
7	<b>Profit after finance costs but before exceptional items ( 5-6)</b>	<b>169.44</b>	<b>157.09</b>	<b>110.41</b>	<b>471.15</b>	<b>398.59</b>	<b>551.51</b>
8	Exceptional items	0.00	0.00	0	0	00.00	00.00
9	<b>Profit from ordinary activities before tax ( 7+8)</b>	<b>169.44</b>	<b>157.09</b>	<b>110.41</b>	<b>471.15</b>	<b>398.59</b>	<b>551.51</b>
10	Tax expense	8.89	6.17	7.09	19.23	41.50	51.22
11	<b>Profit from ordinary activities after tax (9-10)</b>	<b>160.55</b>	<b>150.92</b>	<b>103.32</b>	<b>451.92</b>	<b>357.09</b>	<b>500.29</b>
12	Exceptional items ( net of tax expense)	00.00	00.00	0.00	0.00	0.00	0.00
13	<b>Net profit for the period ( 11-12)</b>	<b>160.55</b>	<b>150.92</b>	<b>103.32</b>	<b>451.92</b>	<b>357.09</b>	<b>500.29</b>
14	<b>Paid up Equity Share Capital</b>	<b>97.42</b>	<b>97.42</b>	<b>91.42</b>	<b>97.42</b>	<b>91.42</b>	<b>97.42</b>
15	<b>Reserves excluding revaluation reserves</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>N. A.</b>	<b>3,003.48</b>
16	<b>E.P.S - Basic not annualised for the qtr</b>	<b>16.48</b>	<b>15.49</b>	<b>11.30</b>	<b>46.39</b>	<b>39.06</b>	<b>51.35</b>
	- Annualised	<b>65.92</b>	<b>61.97</b>	<b>45.21</b>	<b>61.85</b>	<b>52.08</b>	<b>51.35</b>
	<b>Part - II</b>						
1	<b>Public Shareholding</b>						
	- Number of Shares	6437086	6437086	6388986	6437086	6388986	6388986
	- Percentage of Shareholding	66.08	66.08	69.89	66.08	69.89	65.58
2	<b>Promoters and promoter group shareholding</b>						
a)	<b>Pledged as collateral security to bank</b>						
	- Number of Shares	1430000	1881900	1930000	1881900	1930000	1930000
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	43.27	56.94	70.10	56.94	70.10	57.56
	- Percentage of shares (as a % of the total share capital)	14.67	19.31	21.11	19.31	21.11	19.81
b)	<b>Non-Encumbered</b>						
	- Number of Shares	1874902	1423002	823002	1423002	823002	1423002
	- Percentage of shares (as a % of the total share holding of promoter and promoter group)	56.73	43.06	29.89	43.06	29.89	42.44
	- Percentage of shares (as a % of the total share capital)	19.25	14.61	09.01	14.61	09.01	14.61
	<b>(B) INVESTOR COMPLAINTS</b>						
	Particulars	3 months ended 31.12.12					
	Pending at the beginning of the quarter	NIL					
	Received during the quarter	1					
	Disposed of during the quarter	1					
	Remaining unresolved at the end of the quarter	NIL					

**For VENUS REMEDIES LIMITED**

**CHAIRMAN & MANAGING DIRECTOR**

**VENUS REMEDIES LIMITED**

**Corporate Office :**  
51-52, Industrial Area, Phase-I,  
Panchkula (Hry.) 134113, India  
**Regd. Office :**



**Unit-I :**  
51-52, Industrial Area, Phase-I, Panchkula (Hry.) 134113, India  
Tel. : +91-172-3933094, 3933090, 2565577, Fax : +91-172-2565566  
**Unit-II :**

**Notes:**

1. The above Un-audited (Provisional) financial Results for the period ended 31.12.2012 were reviewed by the Audit Committee and taken on record at the Board Meeting on February 7, 2013.
2. During the Quarter:
  - a) the Company has received approval from Drugs Controller General, India (DCGI) to conduct Phase-III clinical Trials of its Cancer detection NCE (New chemical Entity).
  - b) the Company has secured its first Mexican patent from for its research product "VANCOPLUS".
3. The Statutory Auditors have carried out Limited Review of the above Un- audited financial results in terms of Clause 41 of the listing Agreement.
4. During the Quarter, one investor grievances was received and resolved. No investor grievance was pending at the end of the quarter.
5. The Company caters to only one segment i.e. "Pharmaceutical Formulations".

For and on behalf of Board of Directors  
For VENUS REMEDIES LIMITED

  
(Pawan Chaudhary)  
Chairman & Managing Director

Place : Panchkula  
Date : 07.02.2013